- Home
- GYRE vs TIPT Comparison
GYRE vs TIPT Comparison
Compare GYRE & TIPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- TIPT
- Stock Information
- Founded
- GYRE 2002
- TIPT 2007
- Country
- GYRE United States
- TIPT United States
- Employees
- GYRE N/A
- TIPT N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- TIPT Property-Casualty Insurers
- Sector
- GYRE Health Care
- TIPT Finance
- Exchange
- GYRE Nasdaq
- TIPT Nasdaq
- Market Cap
- GYRE 897.1M
- TIPT 881.6M
- IPO Year
- GYRE N/A
- TIPT 2007
- Fundamental
- Price
- GYRE $8.31
- TIPT $17.47
- Analyst Decision
- GYRE Strong Buy
- TIPT
- Analyst Count
- GYRE 2
- TIPT 0
- Target Price
- GYRE $17.00
- TIPT N/A
- AVG Volume (30 Days)
- GYRE 83.8K
- TIPT 388.5K
- Earning Date
- GYRE 11-12-2025
- TIPT 10-30-2025
- Dividend Yield
- GYRE N/A
- TIPT 1.40%
- EPS Growth
- GYRE N/A
- TIPT 74.19
- EPS
- GYRE 0.02
- TIPT 1.29
- Revenue
- GYRE $102,189,000.00
- TIPT $2,024,136,000.00
- Revenue This Year
- GYRE $16.80
- TIPT N/A
- Revenue Next Year
- GYRE $50.29
- TIPT N/A
- P/E Ratio
- GYRE $181.00
- TIPT $13.33
- Revenue Growth
- GYRE N/A
- TIPT 6.10
- 52 Week Low
- GYRE $6.11
- TIPT $17.07
- 52 Week High
- GYRE $19.00
- TIPT $27.41
- Technical
- Relative Strength Index (RSI)
- GYRE 56.93
- TIPT 33.86
- Support Level
- GYRE $8.17
- TIPT $17.07
- Resistance Level
- GYRE $9.42
- TIPT $18.46
- Average True Range (ATR)
- GYRE 0.39
- TIPT 0.64
- MACD
- GYRE 0.11
- TIPT -0.03
- Stochastic Oscillator
- GYRE 50.22
- TIPT 18.10
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About TIPT Tiptree Inc.
Tiptree Inc is a United States-based company that provides specialty insurance products and related services. It has two reportable segments: Insurance and Mortgage. The company generates the majority of its revenue from the Insurance Segment, which is engaged in designing, marketing, and underwriting specialty property and casualty insurance products incorporating value-added coverages and services for select target markets or niches. The Mortgage segment originates loans for sale to institutional investors, including GSEs and FHA/VA, and services loans on behalf of Fannie Mae, Freddie Mac, and Ginnie Mae.